Bay­er on­col­o­gy vet Robert La­Caze has his eyes on next steps — land­ing his first gig as CEO of Sade­lain co-found­ed biotech

Three weeks af­ter Bay­er put out word that Robert La­Caze, its head of their on­col­o­gy strate­gic busi­ness unit, was jump­ing ship, we now know where he’s head­ed: the transat­lantic T-cell biotech Mnemo Ther­a­peu­tics, where La­Caze will be tak­ing up the helm and mov­ing for­ward as CEO on May 1.

Found­ing CEO Alain Maiore is stay­ing with the com­pa­ny, but is piv­ot­ing his role from CEO to COO.

Michel Sade­lain, the CAR-T re­searcher and Juno co-founder at Memo­r­i­al Sloan Ket­ter­ing, had put his name and cell en­gi­neer­ing tech­nol­o­gy be­hind the start­up when it of­fi­cial­ly launched back in June — and he’s list­ed as a sci­en­tif­ic co-founder. Maiore said at the time that they as a com­pa­ny were ready to bring on the next gen­er­a­tion of cell ther­a­pies in what­ev­er fla­vor they come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER